Eloxx Pharmaceuticals (NASDAQ:ELOX) Releases Earnings Results

Eloxx Pharmaceuticals (NASDAQ:ELOX) posted its quarterly earnings data on Tuesday. The company reported ($0.66) earnings per share (EPS) for the quarter, Zacks reports.

Eloxx Pharmaceuticals Price Performance

Shares of Eloxx Pharmaceuticals stock traded up $2.18 on Tuesday, reaching $19.18. 51,268 shares of the stock were exchanged, compared to its average volume of 57,978. Eloxx Pharmaceuticals has a twelve month low of $8.20 and a twelve month high of $19.96. The company has a 50 day simple moving average of $16.23. The company has a market capitalization of $13.20 million, a price-to-earnings ratio of -1.25 and a beta of -1,864.08.

Analysts Set New Price Targets

Several analysts recently weighed in on ELOX shares. Lifesci Capital initiated coverage on Eloxx Pharmaceuticals in a report on Wednesday, July 22nd. They issued an “outperform” rating and a $40.00 price objective for the company. Wall Street Zen raised Eloxx Pharmaceuticals to a “hold” rating in a research report on Saturday, August 1st. Finally, Guggenheim assumed coverage on shares of Eloxx Pharmaceuticals in a report on Monday, July 20th. They set a “buy” rating and a $43.00 price objective on the stock. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $41.50.

Eloxx Pharmaceuticals Company Profile

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.